| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 29, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
EFFECT - Ernexa Therapeutics Inc. (0000748592) (Filer)
424B3 - Ernexa Therapeutics Inc. (0000748592) (Filer)
S-3 - Ernexa Therapeutics Inc. (0000748592) (Filer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago on April 28. The study showed how engineered cells derived from stem cells could transform the treatment of ovarian cancer. The data revealed that these engineered cells, which release powerful immune-boosting cytokines, not only shrink tumors but also help the body's immune system to attack the cancer more effectively. "We've taken cells that normally help repair tissues in the body and repr
CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The study explored the technology behind Ernexa's lead cell therapy product, ERNA-101, which uses specially engineered cells to deliver treatment directly to ovarian tumors. By secreting immune-stimulating cytokines, this cell therapy treatment aims to reshape the tumor microenvironment and enhance anti-tumor immune responses, fighting off the cancer. The study was led by M
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has entered into a securities purchase agreement with accredited investors for the private placement of approximately 69.3 million shares of common stock (or pre-funded warrants to purchase shares of common stock), at a purchase price of $0.1046 per share for an aggregate purchase price of approximately $7,250,000, assuming the Company receives stockholder approval. "These are very exciting times at Ernexa, as we advance therapeutic innovation in cell therapy for the benefit of pati
CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (NASDAQ:ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena Ratner, M.D., M.B.A, to the Board of Directors. Dr. Ratner will spearhead the strategic direction of Eterna's efforts to combat ovarian cancer, leveraging her extensive expertise in obstetrics, gynecology, and reproductive sciences. Under her leadership, the company aims to accelerate advancements in innovative therapies targeting these high-priority areas in women's health. This direction is bolstered by Eterna's recent collaboration with MD Anderson Cancer Center. Announced last month, the p
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board. "We're honored to have Dr. Mahendra Rao join our Scientific Advisory Board," said Sanjeev Luther, President and CEO of Eterna. "His deep scientific expertise in regenerative medicine and cell engineering will be invaluable to our company in its upcoming phases of scientific and clinical development as we strive to brin
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors. "Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization," said Sanjeev Luther, President and CEO of Eterna. "We are very pleased to have him join our Board to support value creation through the development of next-generation therapies using mRNA cell engineerin
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution of a securities purchase agreement with accredited investors for the sale of approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock in a private placement transaction that was priced at-the-market under Nasdaq rules. The Company expects to hold an initial closing at which it exp
CAMBRIDGE, MASS., July 18, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction that closed on July 14, 2023 and was priced at-the-market under Nasdaq rules. The notes, which were issued at par, bear interest at a rate of 6.0% per year, payable quarterly, and mature in July 2028
Acquisition includes Exacis' entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (NASDAQ:ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics ("Exacis"). The acquisition complements Eterna's core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna with an exclusive g